Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0179

Payer / HTA meeting · Dr. Katarina Rossi

11 Jul 2026 · Phone · Dr. Katarina Rossi, Charité Berlin · MSL James Whitfield · Lumeva

ReviewedManualENG-0179—

Capture insight from this engagement

Location: Charité Berlin
Therapeutic area: Neurology
Country: Germany
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Lumeva (lumevarin)

Topics discussed

Chronic migraine data
Drug interactions
Real-world persistence

Scientific content used

Chronic migraine scientific platform
LMV persistence data summary

Questions raised

What is the persistence rate at 18 months in real-world cohorts?
Any data in patients with medication-overuse headache?

Notes

Payer / HTA meeting with general neurologist at Charité Berlin. Discussed chronic migraine data, drug interactions, real-world persistence.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Schedule follow-up in 6 weeks

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 5
Depth of exchange: 2
Actionability: 3

Data lineage

Source system: Manual
Sync: Entered manually in Hub
System of record: Hub
Record id: ENG-0179

Audit history (0)

All create, update and approval events for this record

No audit events in sample data